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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Connective tissue growth factor (CCN2) has been associated with the
pathogenesis of various fibrotic diseases, including oral submucous fibrosis (OSF). The chemical
constituents of areca nut along with the mechanical trauma cause OSF. The coarse fibers of
areca nut injure the mucosa and hence sphingosine-1-phosphate (S1P) is released at the
wounded sites. Recent studies have shown that S1P is involved in wound healing and the devel-
opment of fibrosis. The aims of this study were to investigate the effects of S1P on CCN2
expression in human buccal fibroblasts (HBFs) and identify the potential targets for drug inter-
vention or chemoprevention of OSF.
Methods: Western blot analyses were used to study the effects of S1P on CCN2 expression and
its signaling pathways in HBFs and whether epigallocatechin-3-gallate (EGCG), the main and
most significant polyphenol in green tea, could inhibit this pathway.
Results: S1P significantly enhanced CCN2 synthesis in HBFs. This effect can be inhibited by c-
Jun NH2-terminal kinase (JNK) inhibitor and extracellular signal-regulated kinase inhibitor but
not by P38 mitogen-activated protein kinase inhibitor. Interestingly, EGCG completely blocked
S1P-induced CCN2 expression via suppressing S1P-induced JNK phosphorylation.of Dentistry, National Taiwan University Hospital, 1 Chang-Te Street, Taipei 10048, Taiwan.
(C.-M. Liu).
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EGCG inhibits S1P-induced CCN2 in buccal cells 861Conclusion: S1P released by repetitive mechanical trauma during AN chewing may contribute
to the pathogenesis of OSF through upregulating CCN2 expression in HBFs. EGCG could be an
adjuvant to the current offered therapy options or the prevention of OSF through suppression
of JNK activation.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
It is generally accepted that areca nut (AN) chewing is
closely related to oral submucous fibrosis (OSF). Epidemi-
ological studies and current investigations suggest that the
chemical constituents and the persistent mucosal trauma
seem to be key to the etiology. This fibrotic disease is
characterized by epithelial atrophy, juxta-epithelial
inflammatory reaction, and progressive fibrosis in the lam-
ina propria and the submucosal tissues.1e3 These changes
gradually lead to mucosal stiffness, trismus, limited tongue
movement, and eventually cause problems with eating,
maintaining oral hygiene, and even speech.
The major alkaloid of areca nut, known as arecoline, has
been found to have several biological effects such as
stimulating collagen synthesis,4 upregulating tissue inhibi-
tor metalloproteinase-15 and connective tissue growth
factor (CCN2),6 and promoting myofibroblast differentia-
tion7 in human fibroblasts. When chewing AN, the coarse
fibers cause trauma to the oral mucosa and the chemical
constituents consecutively diffuse into the subepithelial
connective tissue.8 Furthermore, this traumatization cau-
ses thrombin production, which has been found to correlate
with the pathogenesis of OSF.9 However, the molecular
pathologic mechanism(s) of OSF still remain to be further
clarified.
CCN2 is a 36e38 kDa secreted matricellular protein that
belongs to the CCN family and has been found overex-
pressed in many fibrotic diseases.10 Normally, CCN2
expression is restricted to the glomerular mesangial and
hepatic stellate cells.11 When it is induced by growth fac-
tors, CCN2 is secreted into the extracellular environment
and interacts with extracellular matrix components. It is an
important mediator. It regulates many biological processes
including cell proliferation, adhesion, and migration, and
plays a major role in wound healing.10,11 In addition, it has
also been considered to be a modulator of inflammation
and creates a favorable environment for fibrogenic stimuli
to interact.12,13 Moreover, its overexpression in human
fibrotic diseases is an interesting issue.6,11 By blocking CCN2
action with neutralizing antibodies or with antisense oli-
gonucleotides abrogates both transforming growth factor-b
(TGFb)- and CCN2-mediated extracellular matrix produc-
tion in vitro and in vivo.14 Collectively, CCN2 may therefore
represent a new target for antifibrotic therapy.
Sphingosine-1-phosphate (S1P), a bioactive sphingolipid
metabolite, is an important pleiotropic lysophospholipid
mediator that induces diverse biological activities via
transmitting signals through specific G protein-coupled
receptors. For example, wound healing, cell proliferation,
cell migration, cell differentiation, and the development of
fibrosis.15,16 It presents in human plasma at concentrationsranging from 100 ng/mL to 1000 ng/mL.17 To date, five
members (EDG-1/S1P1, EDG-5/S1P2, EDG-3/S1P3, EDG-6/
S1P4, and EDG-8/S1P5) have been identified. According to
previous studies, S1P1 and S1P3 are involved in the devel-
opment of human liver fibrosis.18 Furthermore, Ikeda et al19
reported that the incidence of carbon tetrachloride- and
dimethylnitrosamine-induced liver fibrosis is significantly
reduced in S1P2 knockout mice as compared with the wild-
type. Reports have shown that S1P induces CCN2 expression
in human endothelial20 and rat glomerular mesangial
cells.21 However, the effects of S1P on CCN2 expression in
human buccal fibroblasts (HBFs) remain obscure.
Recently, we found that epigallocatechin-3-gallate
(EGCG), the most abundant polyphenol in green tea,
inhibits TGFb- and thrombin-induced CCN2 synthesis
completely in HBFs.9,22 The aim of the present study is to
investigate the effect of S1P on CCN2 expression in HBFs
and whether or not EGCG can affect this signaling pathway.
Our findings may provide further useful information for the
treatment of OSF caused by CCN2 overexpression.
Materials and methods
Reagents
S1P, EGCG, and curcumin were from Sigma-Aldrich
(St Louis, MO, USA). Lovastatin was from Standard Chem.
& Pharm. Co. (Tainan, Taiwan). Specific extracellular
signal-regulated kinase (ERK) inhibitor PD98059, c-Jun NH2-
terminal kinase (JNK) inhibitor SP600125, and p38 mitogen-
activated protein kinase (MAPK) inhibitor SB203580 were
obtained from Calbiochem (San Diego, CA, USA). Goat anti-
CCN2 polyclonal antibody, rabbit anti-total JNK polyclonal
antibody, mouse anti-b-actin monoclonal antibody, and
donkey anti-goat, goat anti-mouse, and goat anti-rabbit
horseradish peroxidase-link secondary antibodies were
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Rabbit antibodies against phospho-JNK antibodies were
from Cell Signaling (Beverly, MA, USA). All biological tissue
culture reagents were obtained from Invitrogen (Carlsbad,
CA, USA).
Cell culture
After receiving approval from the National Taiwan Univer-
sity Hospital Research Ethics Committee, four primary HBF
cultures were established by an explant technique as pre-
viously described.6,9 Cells at 4e10 passages were plated on
60 mm Petri dishes at a density of 2  105 cells and sub-
jected to various treatments. Prior to treatment, the cells
were incubated in serum-free media for 18 hours. In
Figure 2 Effects of MAPK inhibitors on the S1P-induced CCN2
expression in HBFs. (A) Cells were pretreated with 10 mM of p38
MAP kinase inhibitor SB203580, 10 mM of JNK inhibitor SP600125
or 10 mM of ERK inhibitor PD98059 for 1 hour, then treated with
1mM S1P for 2 hours. CCN2 levels were measured by western
blot analysis. (B) Results of (A) were quantified using comput-
erized image analysis, normalized by the level of b-actin, and
expressed as fold change relative to untreated controls. Data
are expressed as mean  standard error of the mean (n Z 4,
* p < 0.05 compared with control, ** p < 0.05 compared to 1 mM
S1P).
862 J.I.-C. Sar et al.selected experiments, three groups of HBFs were pre-
treated with 10 mM ERK inhibitor PD98059, 10 mM JNK
inhibitor SP600125, or 10 mM of p38 MAP kinase inhibitor
SB203580 for 1 hour prior to exposure to 1mM S1P for 2
hours. To study the effects of EGCG, curcumin, and lova-
statin, HBFs were pretreated with 10 mM curcumin, 10 mM
EGCG, or 20 mM lovastatin for 1 hour prior to S1P treatment.
Data presented herein are the means of four experiments.
Western blot analysis
Western blot analysis was performed as previously
described.6,9 In brief, cells were harvested, lysed in lysis
buffer, separated by sodium dodecyl sulfa-
teepolyacrylamide gel electrophoresis, and transferred to
PVDF membranes. The membrane was then incubated with
antibodies against CCN2 (1:1000 dilution), b-actin (1:1000),
phosphor-JNK (1:750) or total JNK (1:1000). Primary anti-
bodies were detected with donkey anti-goat or goat anti-
mouse horseradish peroxidase-linked secondary antibodies
(1:10000). For quantitative analysis, we added the Western
Lighting Chemiluminescence Reagent (PerkinElmer, Wal-
tham, MA, USA) on the membrane and analysis was carried
out with a Fuji LAS-4000 lumino image analyzer (Fuji Photo
Film Co., Tokyo, Japan).
Statistical analysis
Group data are expressed as mean  standard error.
The unpaired Student t test was used to compare the group
differences. A p value < 0.05 was considered statistically
significant.
Results
S1P has been detected in human plasma at concentrations
up to 1000 ng/mL. HBFs were therefore first treated with
1 mM S1P for various periods of time. As shown in Fig. 1,
treatment of HBFs with 1 mM S1P led to about three-fold
increase of CCN2 protein expression which reached its
peak level after 2 hours treatment and decreased to control
level thereafter. HBFs were then pretreated with 10 mM ERK
inhibitor PD98059, 10 mM JNK inhibitor SP600125, or 10 mM
p38 MAP kinase inhibitor SB203580 for 1 hour prior to
exposure to 1 mM S1P for 2 hours to investigate the MAPK
signaling pathway in the S1P-induced CCN2 protein
expression. Results revealed that after pretreatment with
SP600125 and PD98059, the S1P-induced CCN2 protein was
reduced by approximately 79.7% and 62.1%, respectively
(Fig. 2). However, pretreatment with SB203580 had no
significant effect on the S1P-induced CCN2 proteinFigure 1 Sphingosine-1-phosphate (S1P) stimulates CCN2
expression in human buccal fibroblasts (HBFs). Cells were
treated with 1 mM S1P for various periods of time. CCN2 protein
levels were measured by western blot analysis.expression. We next examined whether EGCG, curcumin, or
lovastatin inhibited S1P-induced CCN2 protein expression in
HBFs. As shown in Fig. 3, only EGCG significantly inhibited
S1P-induced CCN2 protein expression and the inhibition is
dose-dependent. At concentration of 10 mM, EGCG almost
completely inhibited S1P-induced CCN2 protein expression.
EGCG significantly decreased the S1P-induced JNK phos-
phorylation (Fig. 4).
Discussion
Elevated levels of CCN2 were found in almost all human
fibrotic disorders and are suggested to be involved in the
development and progression of fibrotic diseases.11 CCN2
was recently found to be overexpressed in OSF.6 Constitu-
tive CCN2 overexpression may play an important role in the
pathogenesis of OSF. In this study, we found CCN2 expres-
sion stimulated by S1P in HBFs. Repetitive microtrauma
during AN chewing causes S1P release and may contribute
to the pathogenesis of OSF by inducing CCN2 expression.
Multiple signaling pathways have been shown to regulate
CCN2 expression.23 Identifying the signaling molecules
associated with S1P-induced CCN2 expression in HBFs can
provide more information for the development of better
strategies to treat OSF. Previous studies have shown that
S1P-induced CCN2 expression is through the activation of
Figure 3 Epigallocatechin-3-gallate (EGCG) inhibits S1P-
induced CCN2 in HBMFs. Cells were pretreated with 20 mM
lovastatin, 10 mM EGCG, or 10 mM curcumin for 1 hour, then (A)
treated with 1 mM S1P for 2 hours or (B) pretreated with
increasing concentrations of EGCG (0e15 mM) for 1 hour prior
to exposure to 1 mM S1P for 2 hours (B). CCN2 levels were
measured by western blot analysis.
EGCG inhibits S1P-induced CCN2 in buccal cells 863small GTPases of the Rho family in human endothelial20 and
rat glomerular mesangial cells.21 Most of these small
GTPases undergo post-translational isoprenylation, which is
essential for their proper subcellular localization and bio-
logical function.24 Statins have been shown to abrogate the
biological functions of the small GTPases through their in-
hibition of protein isoprenylation.24 Pretreatment HBFs
with lovastatin did not significantly affect the expression of
CCN2 protein in S1P treated HGFs indicating that small
GTPases of the Rho family are not involved in the S1P-
induced CCN2 expression.
In addition to the canonical Smad-mediated pathway,
TGFb-induced CCN2 expression in fibroblasts is also modu-
lated by MAPK signaling.22,25,26 In gingival fibroblasts, Black
et al25 found that TGFb induced CCN2 expression through
JNK, but not Ras/MEK/ERK in gingival fibroblasts. Stratton
et al26 reported that Ras/MEK/ERK stimulates TGFb-
induced CCN2 expression in dermal fibroblasts whereas JNK
suppresses the reaction. Recently, we found that TGFb1
induced CCN2 expression through JNK and p38 MAPK but not
ERK in HBFs.22 Our present study shows that inhibitors ofFigure 4 Epigallocatechin-3-gallate (EGCG) significantly
inhibited S1P-induced JNK phosphorylation.JNK and ERK but not MAPK suppress S1P-induced CCN2
expression in HBFs. This result suggests that S1P-induced
CCN2 expression is mediated via JNK and ERK but not p38
MAPK in HBFs and is consistent with the opinions that CCN2
expression is regulated in a cell type and context specific
manner.
To date, no known treatment for OSF is effective in
reversing the disease. Our previous studies revealed that
curcumin can completely inhibit arecoline-induced CCN2
synthesis in HBFs.6 EGCG inhibits TGFb- and thrombin-
induced CCN2 synthesis completely by suppressing JNK in
HBFs.9,22 In addition, EGCG can also inhibit arecoline-
induced CCN2 synthesis (our unpublished observations).
We therefore pretreated primary HBFs with curcumin or
EGCG to test their inhibitory effects on S1P-induced CCN2
expression in HBFs. Our results revealed that EGCG, but not
curcumin, completely blocks the S1P-induced CCN2
expression and JNK phosphorylation in HGFs. These results
strengthen the usage of EGCG for the prevention and
treatment of OSF.
In conclusion, this study demonstrates, for the first time
to our knowledge, that S1P stimulates CCN2 protein pro-
duction in HBFs. Constitutive CCN2 overexpression may
enhance the profibrotic activity in OSF. The S1P-induced
CCN2 expression could be completely blocked by EGCG.
EGCG could be an adjuvant to the current offered therapy
options or the prevention of OSF through suppression of JNK
activation.
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